LEO Pharma's Data Blitz Aims to Redefine Dermatological Care

MADISON, NJ – March 20, 2026

As the dermatology world prepares to convene in Denver for the 2026 American Academy of Dermatology (AAD) Annual Meeting, LEO Pharma is positioning itself for a landmark presence. The global medical dermatology leader has announced it will present 17 scientific abstracts, its largest body of research to date at the prestigious conference. The data spans its portfolio for challenging inflammatory skin diseases, including Atopic Dermatitis (AD), Chronic Hand Eczema (CHE), and the rare, life-threatening Generalized Pustular Psoriasis (GPP).

The extensive presentation slate signals a clear strategy focused on generating long-term and real-world evidence to address persistent gaps in patient care. “We’re proud to present LEO Pharma’s largest body of research to date at the AAD Annual Meeting, highlighting new real-world and clinical insights,” said Sophie Lamle, EVP, Development at LEO Pharma. “Together, these findings reflect continued advancements in the understanding and management of chronic dermatologic diseases and underscore our ambition to help address critical treatment gaps for patients.”

Beyond the Clinical Trial: A Focus on Real-World, Inclusive Care

A significant theme emerging from LEO Pharma’s AAD agenda is a deep investment in Real-World Evidence (RWE)—data collected outside the rigid confines of traditional randomized controlled trials (RCTs). This approach is critical for understanding how therapies perform in the messy, diverse reality of daily clinical practice. The centerpiece of this effort is the 12-month data from the TRACE study for ADBRY® (tralokinumab) in atopic dermatitis.

Crucially, the study includes dedicated analyses on the safety and effectiveness of ADBRY in patients with skin of color, as well as those with stubborn AD on the hands and feet. This focus on inclusivity directly addresses a long-standing issue in dermatology, where clinical trial populations have often failed to reflect the full spectrum of patients, leading to evidence gaps for clinicians treating diverse communities. By providing specific data on these underserved groups, LEO Pharma aims to give healthcare providers greater confidence in tailoring treatments for individuals who may have been underrepresented in foundational studies.

The growing acceptance of RWE by regulatory bodies like the FDA and EMA further validates this strategy. Such data is increasingly seen as essential for bridging the gap between clinical efficacy and real-world effectiveness, informing treatment guidelines, and supporting market access by demonstrating value across a broader patient base.

Navigating a Crowded and Competitive Landscape

LEO Pharma's data deluge arrives at a time of intense competition across the inflammatory skin disease market. The company's presentations appear to be a calculated move to reinforce the value of its key assets—ADBRY®, ANZUPGO®, and SPEVIGO®—in highly dynamic therapeutic areas.

In the atopic dermatitis space, ADBRY, an IL-13 inhibitor, contends with the market-leading IL-4Rα inhibitor Dupixent® and a growing field of oral JAK inhibitors and emerging biologics. For instance, Sanofi is expected to present pivotal Phase 3 data for its anti-OX40 ligand antibody, amlitelimab, at the same conference. Against this backdrop, LEO Pharma's focus on real-world effectiveness and specific patient subgroups like those with skin of color is a key differentiation strategy, moving the conversation from pure efficacy metrics to practical, long-term patient management.

The landscape for chronic hand eczema is also heating up. LEO Pharma's ANZUPGO® (delgocitinib) cream, the first topical pan-JAK inhibitor for CHE, will now face a new challenger. Pfizer is set to present Phase 3 results for its oral JAK1 inhibitor, abrocitinib, in CHE at AAD 2026. This sets the stage for a clinical debate on the merits of a targeted topical approach versus a systemic one, making LEO Pharma’s data on long-term outcomes and quality of life for ANZUPGO particularly relevant for clinicians weighing treatment options.

For the rare and severe condition of Generalized Pustular Psoriasis, SPEVIGO® (spesolimab) was a first-in-class therapy targeting the IL-36 pathway for acute flares. The long-term data from the EFFISAYIL program, evaluating both intravenous treatment and a subcutaneous formulation for flare prevention, is designed to solidify its position as the standard of care. This research aims to demonstrate SPEVIGO’s utility not just as an emergency intervention but as a cornerstone of long-term disease management, a critical need for patients living under the constant threat of debilitating flares.

Redefining Success with Long-Term Quality of Life

Beyond skin clearance, LEO Pharma's research places a strong emphasis on a metric that matters profoundly to patients: quality of life. For individuals battling chronic skin conditions, the daily burden of pain, itch, functional impairment, and psychological distress can be immense. Patient advocacy groups like the National Eczema Association and the GPP Alliance consistently highlight these impacts as central to the patient experience.

LEO Pharma’s presentations directly address this. Data from the DELTA 3 trial for ANZUPGO cream will highlight sustained improvements in health-related quality of life for people with chronic hand eczema. For a condition that can cripple one's ability to work, perform daily tasks, and interact socially, evidence of durable relief is a powerful message. Similarly, the CHECK study results will shed light on patient-perceived factors and the broader quality-of-life burden associated with CHE in the United States.

This patient-centric focus extends to GPP, where the fear and anxiety over unpredictable, life-threatening flares are a constant presence. The long-term data on subcutaneous SPEVIGO for flare prevention speaks directly to this unmet need, offering the potential for patients to regain a sense of control and normalcy. By quantifying these improvements, LEO Pharma is building a case for its therapies based not just on clinical endpoints, but on their ability to fundamentally improve the lives of those they are designed to help.

The company's comprehensive research program at AAD 2026, which also includes new insights into Pyoderma Gangrenosum and Psoriasis, paints a picture of a company deeply invested in the complexities of dermatological disease. By pushing for more inclusive data, navigating a competitive market with strategic evidence, and prioritizing the long-term well-being of patients, LEO Pharma is making a clear statement about its commitment to shaping the future of skin health.